Sight Sciences Inc. (NASDAQ: SGHT) President and CEO Paul Badawi completed a share sale totaling $155,467 on July 1, 2026. The transaction involved the disposition of 28,684 common shares. Each share was sold at a weighted average price of $5.42. Individual transaction prices for these shares ranged from $5.24 to $5.58. The sale was executed specifically to cover tax liabilities arising from the vesting of restricted stock units.
Following this transaction, Badawi directly holds 6,122,472 shares of Sight Sciences common stock. This total includes 5,572,746 shares of common stock and 549,726 shares that remain to be acquired upon the vesting and settlement of restricted stock units. Badawi serves as President and CEO and also holds a director position. He is classified as a ten percent owner of the company.
Sight Sciences common stock currently trades at $5.48. This pricing places the medical device company at a market capitalization of $300 million. According to InvestingPro analysis, SGHT appears overvalued relative to its Fair Value estimate. The stock has delivered a 30% return over the past year. An InvestingPro Tip notes that price movements remain quite volatile.
Recent financial results present a mixed outcome for the company. Sight Sciences reported Q1 2026 earnings showing revenue of $19.7 million. This figure surpassed expectations by 6.2%. However, earnings per share came in at -$0.24. This result was 41.18% below forecasts. These developments highlight the company's ability to generate revenue while also indicating challenges in profitability.
No significant fluctuations in the stock price were observed following the earnings announcement. There were no reports of mergers or acquisitions involving Sight Sciences. Additionally, there were no updates regarding analyst upgrades or downgrades for the company. The financial results provide a snapshot of the company's current performance.
Investors can access a comprehensive Pro Research Report covering SGHT and 1,400+ other US equities for deeper insights.